ClinicalTrials.gg
CompletedNCT02403674DRIVE-AHEADUpdated Nov 20, 2024Results posted

Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)

A Phase 3 interventional study of Doravirine, Tenofovir, Lamivudine and ATRIPLA™ in Human Immunodeficiency Virus (HIV), sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-20.

Primary conditionAcquired Immunodeficiency Syndrome(the registry's first term)UnverifiedIs this wrong?The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
734
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to compare the antiretroviral activity of doravirine, tenofovir, lamivudine (MK-1439A), a single-tablet, once-daily (q.d.) fixed-dose combination (FDC) containing doravirine (MK-1439A) 100 mg + lamivudine 300 mg + tenofovir disoproxil fumarate 300 mg, with ATRIPLA™, a single-tablet FDC containing efavirenz 600 mg + emtricitabine 200 mg + tenofovir disoproxil fumarate 300 mg, in treatment-naive participants infected with human immunodeficiency virus (HIV). The primary hypothesis is that doravirine, tenofovir, lamivudine q.d. is non-inferior to ATRIPLA™ q.d. as assessed by the proportion of participants with HIV-1 ribonucleic acid (RNA) \<50 copies/mL (by the Abbott RealTime HIV-1 Assay) at Week 48. This study has a total duration of 384 weeks, including a 96-week double-blind period and an additional 288-week open-label period.

Read the detailed description

Participants in Australia, Colombia, Guatemala, Honduras, Israel, New Zealand, Peru, Russia, South Africa, and Thailand who are deriving benefit from doravirine, tenofovir, lamivudine are also eligible to continue receiving study drug during additional open-label extensions which will last for 2 years or until drug is available locally, whichever comes first.

02

Conditions studied

  • Human Immunodeficiency Virus (HIV)

Browse trials for

03

In context

Acquired Immunodeficiency Syndrome Unverified

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

This study's enrollment of 734 is above the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is -1 positive as determined by a positive result on an enzyme-immunoassay, has screening plasma HIV-1 RNA (determined by the central laboratory) ≥1000 copies/mL within 45 days prior to the treatment phase of this study, and has HIV treatment indicated based on physician assessment
  • Has never received antiretroviral therapy (ART)
  • Is highly unlikely to either become pregnant or impregnate a partner

Exclusion criteria

Exclusion Criteria:

  • Has a history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound results of the study
  • Is a user of recreational or illicit drugs or has a recent history of alcohol/drug abuse
  • Has been treated for a viral infection other than -1 (e.g., ) with an agent that is active against HIV-1
  • Has participated in a study with an drug/device within 30 days prior to Screening
  • Has used systemic therapy or immune modulators within 30 days prior to treatment in this study or is anticipated to need them during the course of the study
  • Has a current (active) diagnosis of acute hepatitis due to any cause (note: participants with chronic hepatitis B and C may enter the study as long as they fulfill all entry criteria, have stable liver function tests, and have no significant impairment of hepatic synthetic function)
  • Is a female who is pregnant, breastfeeding, or expecting to conceive
  • Is a female and is expecting to donate eggs or is male and is expecting to donate sperm (investigators will provide appropriate guidance regarding egg and/or sperm donation after completion of the study treatment regimen)
  • Has evidence of decompensated liver disease manifested by the presence of or a history of ascites, esophageal or gastric variceal bleeding, hepatic encephalopathy or other signs or symptoms of advanced liver diseases, or has liver cirrhosis and a Class C score or Pugh-Turcotte (CPT) score > 9
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
734 participants (actual)

Study arms

  • Experimental
    Doravirine, Tenofovir, Lamivudine

    Treatment-naive HIV-infected participants will receive doravirine, tenofovir, lamivudine, a single-tablet FDC containing doravirine 100 mg + lamivudine 300 mg + tenofovir disoproxil fumarate 300 mg, q.d. by mouth for 96 weeks. Participants will also take 1 placebo tablet matched to ATRIPLA™ q.d. by mouth for 96 weeks in order to maintain blinding.

    Drug: Doravirine, Tenofovir, Lamivudine · Drug: Placebo

  • Active comparator
    ATRIPLA™

    Treatment-naive HIV-infected participants will receive ATRIPLA™, a single-tablet FDC containing efavirenz 600 mg + emtricitabine 200 mg + tenofovir disoproxil fumarate 300 mg (equivalent to 245 mg tenofovir disoproxil), q.d. by mouth for 96 weeks. Participants will also take 1 placebo tablet matched to doravirine, tenofovir, lamivudine q.d. by mouth for 96 weeks in order to maintain blinding.

    Drug: ATRIPLA™ · Drug: Placebo

Interventions

  • DrugDoravirine, Tenofovir, Lamivudine

    Drug pages: Doravirine · Tenofovir · Lamivudine

    One doravirine, tenofovir, lamivudine tablet taken q.d. by mouth.

    Also known as: MK-1439A

  • DrugATRIPLA™

    One ATRIPLA™ tablet taken q.d. by mouth

  • DrugPlacebo

    Placebo tablets matched to ATRIPLA® or Doravirine, Tenofovir, Lamivudine.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48

    The percentage of participants in each arm with HIV-1 RNA levels \<50 copies/mL at Week 48 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach in which all missing data are considered treatment failures, regardless of the reason.

    Time frame: Week 48

  2. Percentage of Participants With Tier-1 Neuropsychiatric Adverse Events (AEs)

    The percentage of participants in each arm experiencing ≥1 pre-specified Tier-1 neuropsychiatric AEs was determined. The list of Tier-1 neuropsychiatric AE categories included "dizziness", "sleep disorders and disturbances", and "altered sensorium" (including disturbance in attention).

    Time frame: Up to Week 48

Secondary outcomes

  1. Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 96

    The percentage of participants in each arm with HIV-1 RNA levels \<50 copies/mL at Week 96 were determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. The US Food and Drug Administration (FDA) "snapshot" approach (i.e., all missing data handled as treatment failures, regardless of the reason) were used for efficacy analyses.

    Time frame: Week 96

  2. Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 48

    The percentage of participants in each arm with HIV-1 RNA levels \<40 copies/mL (including target detected and target not detected) at Week 48 was determined. Plasma HIV RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach in which all missing data are considered treatment failures, regardless of the reason.

    Time frame: Week 48

  3. Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 96

    The percentage of participants in each arm with HIV-1 RNA levels \<40 copies/mL (including target detected and target not detected) at Week 96 were determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. The US Food and Drug Administration (FDA) "snapshot" approach (i.e., all missing data handled as treatment failures, regardless of the reason) were used for efficacy analyses.

    Time frame: Week 96

  4. Change From Baseline in CD4 Cell Counts at Week 48

    The mean change from baseline in CD4 cell counts at Week 48 was assessed using the Observed Failure (OF) approach. With the OF approach, baseline values were carried forward for participants who discontinued prior to Week 48 due to lack of efficacy. Cell counts at Baseline and Week 48 were measured and expressed as cells/mm\^3, and percent change was then calculated as \[(Baseline counts - Week 48 counts)\*100\]. CD4 cell counts were quantified by a central laboratory using a commercially available assay.

    Time frame: Baseline (Day 1) and Week 48

  5. Change From Baseline in CD4 Cell Counts at Week 96

    The mean change from baseline in CD4 cell counts at Week 96 were assessed using the OF approach. With the OF approach, baseline values were carried forward for participants who discontinued prior to Week 96 due to lack of efficacy. Cell counts at Baseline and Week 96 were measured and expressed as cells/mm\^3, and percent change was calculated as \[(Baseline counts - Week 96 counts)\*100\]. CD4 cell counts were quantified by a central laboratory using a commercially available assay.

    Time frame: Baseline (Day 1) and Week 96

  6. Percentage of Participants Experiencing ≥1 AE

    An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

    Time frame: Up to Week 48

  7. Percentage of Participants Discontinuing From Study Medication Due to an AE(s)

    An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

    Time frame: Up to Week 48

  8. Percentage of Participants With Tier-2 Neuropsychiatric AEs

    The percentage of participants in each arm experiencing ≥1 pre-specified Tier-2 neuropsychiatric AEs was determined. The list of Tier-2 neuropsychiatric AE categories included "depression and suicide/self-injury" and "psychosis and psychotic disorders".

    Time frame: Up to Week 48

  9. Change From Baseline in Fasting LDL-C at Week 48

    The mean percent change from baseline in fasting (fast duration of ≥8 hours) LDL-C levels at Week 48 was determined for each arm. The Last Observation Carry Forward (LOCF) approach was applied to missing data and data collected after a participant initiated lipid-modifying therapy.

    Time frame: Baseline (Day 1) and Week 48

  10. Change From Baseline in Fasting Non-HDL-C at Week 48

    The mean percent change from baseline in fasting (fast duration of ≥8 hours) non-HDL-C levels at Week 48 was determined for each arm. The LOCF approach was applied to missing data and data collected after a participant initiated lipid-modifying therapy.

    Time frame: Baseline (Day 1) and Week 48

  11. Change From Baseline in Fasting Cholesterol at Week 48

    The mean percent change from baseline in fasting (fast duration of ≥8 hours) cholesterol levels at Week 48 was determined for each arm. The LOCF approach was applied to missing data and data collected after a participant initiated lipid-modifying therapy.

    Time frame: Baseline (Day 1) and Week 48

  12. Change From Baseline in Fasting Triglycerides at Week 48

    The mean percent change from baseline in fasting (fast duration of ≥8 hours) triglycerides levels at Week 48 was determined for each arm. The LOCF approach was applied to missing data and data collected after a participant initiated lipid-modifying therapy.

    Time frame: Baseline (Day 1) and Week 48

  13. Change From Baseline in Fasting HDL-C at Week 48

    The mean percent change from baseline in fasting (fast duration of ≥8 hours) HDL-C levels at Week 48 was determined for each arm. The LOCF approach was applied to missing data and data collected after a participant initiated lipid-modifying therapy.

    Time frame: Baseline (Day 1) and Week 48

  14. Percentage of Participants With HIV-1 RNA Below the Limit of Quantification (BLoQ) at Week 48

    The percentage of participants in each arm with HIV-1 RNA levels BLoQ of 40 copies/mL and target not detected at Week 48 was determined. Plasma HIV RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled as observed.

    Time frame: Week 48

  15. Percentage of Participants With HIV-1 RNA BLoQ at Week 96

    The percentage of participants in each arm with HIV-1 RNA levels BLoQ of 40 copies/mL and target not detected at Week 96 was determined. Plasma HIV RNA levels was quantified with the Abbott RealTime HIV-1 Assay. Data was handled as observed.

    Time frame: Week 96

  16. Plasma Concentration of Doravirine at Week 48

    Plasma samples were collected for analysis of doravirine concentration at Week 48. A total of 2 samples were collected: 1 prior to dosing and 1 collected between 0.5 and 2 hours post-dose.

    Time frame: 0 hours post-dose and 2 hours post-dose on Week 48

07

Results

Posted Apr 30, 2018

Participant flow

Treatment-naïve participants with HIV-1 infection have been recruited at 141 study sites worldwide. The present results include results from the base study (first 96-weeks of the study) along with study extension 1 (week 96-192), study extension 2 (week 192-288), and study extension 3 (week 288-384).

Base Study
Participant flow — Base Study
MilestoneMK-1439A (DOR/3TC/TDF From Day 1)ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96)
Started368366
Treated364364
Completed296276
Not completed7290
Withdrew: Death14
Withdrew: Adverse event1126
Withdrew: Lack of efficacy3123
Withdrew: Lost to follow-up68
Withdrew: Withdrawal by subject1017
Withdrew: Physician decision22
Withdrew: Pregnancy22
Withdrew: Protocol violation84
Withdrew: Non-compliance with study drug14
Study Extension 1 (Open-Label)
Participant flow — Study Extension 1 (Open-Label)
MilestoneMK-1439A (DOR/3TC/TDF From Day 1)ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96)
Started291269
Completed230205
Not completed6164
Withdrew: Adverse event14
Withdrew: Lack of efficacy1013
Withdrew: Lost to follow-up85
Withdrew: Withdrawal by subject1113
Withdrew: Physician decision25
Withdrew: Pregnancy42
Withdrew: Death10
Withdrew: Availability of study drug locally2219
Withdrew: Non-compliance23
Study Extension 2 (Open-Label)
Participant flow — Study Extension 2 (Open-Label)
MilestoneMK-1439A (DOR/3TC/TDF From Day 1)ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96)
Started192173
Completed150132
Not completed4241
Withdrew: Lack of efficacy11
Withdrew: Lost to follow-up17
Withdrew: Withdrawal by subject86
Withdrew: Physician decision11
Withdrew: Pregnancy01
Withdrew: Death22
Withdrew: Availability of study drug locally2723
Withdrew: Non-compliance with study drug20
Study Extension 3 (Open-Label)
Participant flow — Study Extension 3 (Open-Label)
MilestoneMK-1439A (DOR/3TC/TDF From Day 1)ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96)
Started121111
Completed10085
Not completed2126
Withdrew: Lost to follow-up54
Withdrew: Withdrawal by subject13
Withdrew: Physician decision15
Withdrew: Pregnancy01
Withdrew: Availability of study drug locally1413

Outcome measures

PrimaryPercentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48

The percentage of participants in each arm with HIV-1 RNA levels \<50 copies/mL at Week 48 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach in which all missing data are considered treatment failures, regardless of the reason.

Time frame:
Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48
Percentage of ParticipantsMK-1439A (DOR/3TC/TDF From Day 1)ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96)
Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 4884.380.8
Statistical analysis
  • MK-1439A (DOR/3TC/TDF From Day 1) vs ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) · Difference in percentages: 3.537 · 95% CI -1.951 to 9.026The 95% CIs for difference in percentages were calculated using stratum-adjusted Mantel-Haenszel method for each stratum (HIV-1 RNA ≤100,000 or \>100,000 copies/mL).
PrimaryPercentage of Participants With Tier-1 Neuropsychiatric Adverse Events (AEs)

The percentage of participants in each arm experiencing ≥1 pre-specified Tier-1 neuropsychiatric AEs was determined. The list of Tier-1 neuropsychiatric AE categories included "dizziness", "sleep disorders and disturbances", and "altered sensorium" (including disturbance in attention).

Time frame:
Up to Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants With Tier-1 Neuropsychiatric Adverse Events (AEs)
Percentage of ParticipantsMK-1439A (DOR/3TC/TDF From Day 1)ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96)
Dizziness8.837.1
Sleep disorders and disturbances12.125.5
Altered sensorium4.48.2
Statistical analysis
  • MK-1439A (DOR/3TC/TDF From Day 1) vs ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) · t-test, 2 sided · p = <0.001 (2-sided P-value) · Difference in percentages: -28.3 · 95% CI -34.0 to -22.595% CIs were calculated using the Miettinen and Nurminen method.
  • MK-1439A (DOR/3TC/TDF From Day 1) vs ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) · t-test, 2 sided · p = <0.001 (2-sided P-value) · Difference in percentages: -13.5 · 95% CI -19.1 to -7.995% CIs were calculated using the Miettinen and Nurminen method.
  • MK-1439A (DOR/3TC/TDF From Day 1) vs ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) · t-test, 2 sided · p = 0.033 (2-sided P-value) · Difference in percentages: -3.8 · 95% CI -7.6 to -0.395% CIs were calculated using the Miettinen and Nurminen method.
SecondaryPercentage of Participants With HIV-1 RNA <50 Copies/mL at Week 96

The percentage of participants in each arm with HIV-1 RNA levels \<50 copies/mL at Week 96 were determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. The US Food and Drug Administration (FDA) "snapshot" approach (i.e., all missing data handled as treatment failures, regardless of the reason) were used for efficacy analyses.

Time frame:
Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 96
Percentage of participantsMK-1439A (DOR/3TC/TDF From Day 1)ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96)
Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 9677.5 (72.8 to 81.7)73.6 (68.8 to 78.1)
Statistical analysis
  • MK-1439A (DOR/3TC/TDF From Day 1) vs ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) · Difference in percentages: 3.815 · 95% CI -2.412 to 10.042The 95% CIs for difference in percentages were calculated using stratum-adjusted Mantel-Haenszel method for each stratum (HIV-1 RNA ≤100,000 or \>100,000 copies/mL).
SecondaryPercentage of Participants With HIV-1 RNA <40 Copies/mL at Week 48

The percentage of participants in each arm with HIV-1 RNA levels \<40 copies/mL (including target detected and target not detected) at Week 48 was determined. Plasma HIV RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach in which all missing data are considered treatment failures, regardless of the reason.

Time frame:
Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 48
Percentage of ParticipantsMK-1439A (DOR/3TC/TDF From Day 1)ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96)
Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 4883.8 (79.6 to 87.4)79.7 (75.2 to 83.7)
Statistical analysis
  • MK-1439A (DOR/3TC/TDF From Day 1) vs ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) · Difference in percentages: 4.1 · 95% CI -1.5 to 9.7The 95% CIs for difference in percentages were calculated using stratum-adjusted Mantel-Haenszel method for each stratum (HIV-1 RNA ≤100,000 or \>100,000 copies/mL).
SecondaryPercentage of Participants With HIV-1 RNA <40 Copies/mL at Week 96

The percentage of participants in each arm with HIV-1 RNA levels \<40 copies/mL (including target detected and target not detected) at Week 96 were determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. The US Food and Drug Administration (FDA) "snapshot" approach (i.e., all missing data handled as treatment failures, regardless of the reason) were used for efficacy analyses.

Time frame:
Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 96
Percentage of participantsMK-1439A (DOR/3TC/TDF From Day 1)ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96)
Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 9676.1 (71.4 to 80.4)72.8 (67.9 to 77.3)
Statistical analysis
  • MK-1439A (DOR/3TC/TDF From Day 1) vs ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) · Difference in percentages: 3.268 · 95% CI -3.057 to 9.593The 95% CIs for difference in percentages were calculated using stratum-adjusted Mantel-Haenszel method for each stratum (HIV-1 RNA ≤100,000 or \>100,000 copies/mL).
SecondaryChange From Baseline in CD4 Cell Counts at Week 48

The mean change from baseline in CD4 cell counts at Week 48 was assessed using the Observed Failure (OF) approach. With the OF approach, baseline values were carried forward for participants who discontinued prior to Week 48 due to lack of efficacy. Cell counts at Baseline and Week 48 were measured and expressed as cells/mm\^3, and percent change was then calculated as \[(Baseline counts - Week 48 counts)\*100\]. CD4 cell counts were quantified by a central laboratory using a commercially available assay.

Time frame:
Baseline (Day 1) and Week 48
Reported as:
Mean · Percent Change from Baseline
Change From Baseline in CD4 Cell Counts at Week 48
Percent Change from BaselineMK-1439A (DOR/3TC/TDF From Day 1)ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96)
Change From Baseline in CD4 Cell Counts at Week 48198.4 (180.2 to 216.7)188.4 (169.5 to 207.2)
Statistical analysis
  • MK-1439A (DOR/3TC/TDF From Day 1) vs ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) · Difference in mean %change from baseline: 10.1 · 95% CI -16.1 to 36.395% CIs were calculated based on t-distribution.
SecondaryChange From Baseline in CD4 Cell Counts at Week 96

The mean change from baseline in CD4 cell counts at Week 96 were assessed using the OF approach. With the OF approach, baseline values were carried forward for participants who discontinued prior to Week 96 due to lack of efficacy. Cell counts at Baseline and Week 96 were measured and expressed as cells/mm\^3, and percent change was calculated as \[(Baseline counts - Week 96 counts)\*100\]. CD4 cell counts were quantified by a central laboratory using a commercially available assay.

Time frame:
Baseline (Day 1) and Week 96
Reported as:
Mean · Percentage Change from Baseline
Change From Baseline in CD4 Cell Counts at Week 96
Percentage Change from BaselineMK-1439A (DOR/3TC/TDF From Day 1)ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96)
Change From Baseline in CD4 Cell Counts at Week 96237.7 (214.9 to 260.6)223.0 (198.4 to 247.6)
Statistical analysis
  • MK-1439A (DOR/3TC/TDF From Day 1) vs ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) · Diff in mean % change from baseline: 14.7 · 95% CI -18.7 to 48.2The 95% CI for mean difference in CD4 change was based on t-distribution.
SecondaryPercentage of Participants Experiencing ≥1 AE

An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

Time frame:
Up to Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants Experiencing ≥1 AE
Percentage of participantsMK-1439A (DOR/3TC/TDF From Day 1)ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96)
Percentage of Participants Experiencing ≥1 AE82.790.7
Statistical analysis
  • MK-1439A (DOR/3TC/TDF From Day 1) vs ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) · Difference in percentages: -8.0 · 95% CI -13.0 to -3.195% CIs were calculated with the Miettinen \& Nurminen method.
SecondaryPercentage of Participants Discontinuing From Study Medication Due to an AE(s)

An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

Time frame:
Up to Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants Discontinuing From Study Medication Due to an AE(s)
Percentage of participantsMK-1439A (DOR/3TC/TDF From Day 1)ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96)
Percentage of Participants Discontinuing From Study Medication Due to an AE(s)3.06.6
Statistical analysis
  • MK-1439A (DOR/3TC/TDF From Day 1) vs ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) · Difference in percentages: -3.6 · 95% CI -6.9 to -0.595% CIs were calculated with the Miettinen \& Nurminen method.
SecondaryPercentage of Participants With Tier-2 Neuropsychiatric AEs

The percentage of participants in each arm experiencing ≥1 pre-specified Tier-2 neuropsychiatric AEs was determined. The list of Tier-2 neuropsychiatric AE categories included "depression and suicide/self-injury" and "psychosis and psychotic disorders".

Time frame:
Up to Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants With Tier-2 Neuropsychiatric AEs
Percentage of ParticipantsMK-1439A (DOR/3TC/TDF From Day 1)ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96)
Depression and suicide/self-injury4.16.6
Psychosis and psychotic disorders0.31.1
Statistical analysis
  • MK-1439A (DOR/3TC/TDF From Day 1) vs ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) · t-test, 2 sided · p = <0.001 (2-sided P-value) · Difference in percentages: -2.5 · 95% CI -5.9 to 0.895% CIs were calculated using the Miettinen and Nurminen method.
  • MK-1439A (DOR/3TC/TDF From Day 1) vs ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) · t-test, 2 sided · p = <0.001 (2-sided P-value) · Difference in percentages: -0.8 · 95% CI -2.5 to 0.595% CIs were calculated using the Miettinen and Nurminen method.
SecondaryChange From Baseline in Fasting LDL-C at Week 48

The mean percent change from baseline in fasting (fast duration of ≥8 hours) LDL-C levels at Week 48 was determined for each arm. The Last Observation Carry Forward (LOCF) approach was applied to missing data and data collected after a participant initiated lipid-modifying therapy.

Time frame:
Baseline (Day 1) and Week 48
Reported as:
Mean · Percent Change from Baseline
Change From Baseline in Fasting LDL-C at Week 48
Percent Change from BaselineMK-1439A (DOR/3TC/TDF From Day 1)ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96)
Change From Baseline in Fasting LDL-C at Week 48-1.58 (-3.98 to 0.81)8.74 (5.86 to 11.62)
Statistical analysis
  • MK-1439A (DOR/3TC/TDF From Day 1) vs ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) · ANCOVA · p = <0.0001 · Difference in mean %change from baseline: -10.01 · 95% CI -13.53 to -6.4995% CIs and 2-sided p-values for treatment difference were calculated from an ANCOVA model with terms for baseline lipid level and treatment.
SecondaryChange From Baseline in Fasting Non-HDL-C at Week 48

The mean percent change from baseline in fasting (fast duration of ≥8 hours) non-HDL-C levels at Week 48 was determined for each arm. The LOCF approach was applied to missing data and data collected after a participant initiated lipid-modifying therapy.

Time frame:
Baseline (Day 1) and Week 48
Reported as:
Mean · Percent Change from Baseline
Change From Baseline in Fasting Non-HDL-C at Week 48
Percent Change from BaselineMK-1439A (DOR/3TC/TDF From Day 1)ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96)
Change From Baseline in Fasting Non-HDL-C at Week 48-3.83 (-6.27 to -1.40)13.26 (10.07 to 16.45)
Statistical analysis
  • MK-1439A (DOR/3TC/TDF From Day 1) vs ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) · ANCOVA · p = <0.0001 · Difference in mean %change from baseline: -17.02 · 95% CI -20.89 to -13.1695% CIs and 2-sided p-values for treatment difference were calculated from an ANCOVA model with terms for baseline lipid level and treatment.
SecondaryChange From Baseline in Fasting Cholesterol at Week 48

The mean percent change from baseline in fasting (fast duration of ≥8 hours) cholesterol levels at Week 48 was determined for each arm. The LOCF approach was applied to missing data and data collected after a participant initiated lipid-modifying therapy.

Time frame:
Baseline (Day 1) and Week 48
Reported as:
Mean · Percent Change from Baseline
Change From Baseline in Fasting Cholesterol at Week 48
Percent Change from BaselineMK-1439A (DOR/3TC/TDF From Day 1)ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96)
Change From Baseline in Fasting Cholesterol at Week 48-1.97 (-4.74 to 0.79)21.77 (18.35 to 25.18)
Statistical analysis
  • MK-1439A (DOR/3TC/TDF From Day 1) vs ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) · Difference in mean %change from baseline: -23.44 · 95% CI -27.57 to -19.3295% CIs for treatment difference were calculated from an ANCOVA model with terms for baseline lipid level and treatment.
SecondaryChange From Baseline in Fasting Triglycerides at Week 48

The mean percent change from baseline in fasting (fast duration of ≥8 hours) triglycerides levels at Week 48 was determined for each arm. The LOCF approach was applied to missing data and data collected after a participant initiated lipid-modifying therapy.

Time frame:
Baseline (Day 1) and Week 48
Reported as:
Mean · Percent Change from Baseline
Change From Baseline in Fasting Triglycerides at Week 48
Percent Change from BaselineMK-1439A (DOR/3TC/TDF From Day 1)ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96)
Change From Baseline in Fasting Triglycerides at Week 48-12.40 (-19.66 to -5.15)22.01 (11.68 to 32.34)
Statistical analysis
  • MK-1439A (DOR/3TC/TDF From Day 1) vs ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) · Difference in mean %change from baseline: -35.96 · 95% CI -47.10 to -24.8295% CIs for treatment difference were calculated from an ANCOVA model with terms for baseline lipid level and treatment.
SecondaryChange From Baseline in Fasting HDL-C at Week 48

The mean percent change from baseline in fasting (fast duration of ≥8 hours) HDL-C levels at Week 48 was determined for each arm. The LOCF approach was applied to missing data and data collected after a participant initiated lipid-modifying therapy.

Time frame:
Baseline (Day 1) and Week 48
Reported as:
Mean · Percent Change from Baseline
Change From Baseline in Fasting HDL-C at Week 48
Percent Change from BaselineMK-1439A (DOR/3TC/TDF From Day 1)ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96)
Change From Baseline in Fasting HDL-C at Week 481.86 (0.83 to 2.89)8.51 (7.32 to 9.69)
Statistical analysis
  • MK-1439A (DOR/3TC/TDF From Day 1) vs ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) · Difference in mean %change from baseline: -6.47 · 95% CI -7.97 to -4.9695% CIs for treatment difference were calculated from an ANCOVA model with terms for baseline lipid level and treatment.
SecondaryPercentage of Participants With HIV-1 RNA Below the Limit of Quantification (BLoQ) at Week 48

The percentage of participants in each arm with HIV-1 RNA levels BLoQ of 40 copies/mL and target not detected at Week 48 was determined. Plasma HIV RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled as observed.

Time frame:
Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants With HIV-1 RNA Below the Limit of Quantification (BLoQ) at Week 48
Percentage of ParticipantsMK-1439A (DOR/3TC/TDF From Day 1)ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96)
Percentage of Participants With HIV-1 RNA Below the Limit of Quantification (BLoQ) at Week 4859.655.5
SecondaryPercentage of Participants With HIV-1 RNA BLoQ at Week 96

The percentage of participants in each arm with HIV-1 RNA levels BLoQ of 40 copies/mL and target not detected at Week 96 was determined. Plasma HIV RNA levels was quantified with the Abbott RealTime HIV-1 Assay. Data was handled as observed.

Time frame:
Week 96
Reported as:
Number · Percentage of Participants
Percentage of Participants With HIV-1 RNA BLoQ at Week 96
Percentage of ParticipantsMK-1439A (DOR/3TC/TDF From Day 1)ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96)
Percentage of Participants With HIV-1 RNA BLoQ at Week 9659.359.1
SecondaryPlasma Concentration of Doravirine at Week 48

Plasma samples were collected for analysis of doravirine concentration at Week 48. A total of 2 samples were collected: 1 prior to dosing and 1 collected between 0.5 and 2 hours post-dose.

Time frame:
0 hours post-dose and 2 hours post-dose on Week 48
Reported as:
Mean · nM
Plasma Concentration of Doravirine at Week 48
nMMK-1439A (DOR/3TC/TDF From Day 1)
Pre-dose1290 ± 799
0.5 to 2 hours post-dose2330 ± 1230

Adverse events

Collected over Up to 430 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DOR/3TC/TDF Only (From Day 1) at Base Study1/368 (0.3%)22/364 (6%)231/364 (63.5%)
DOR/3TC/TDF Switch at Week 96 Base Study4/366 (1.1%)30/364 (8.2%)281/364 (77.2%)
DOR/3TC/TDF Only (DOR/3TC/TDF From Day 1) Ext 12/291 (0.7%)19/291 (6.5%)111/291 (38.1%)
DOR/3TC/TDF Switch (Switch From EFV/FTC/TDF at Week 96) Ext 10/269 (0%)12/269 (4.5%)110/269 (40.9%)
DOR/3TC/TDF Only (DOR/3TC/TDF From Day 1) Ext 22/192 (1%)8/192 (4.2%)—
DOR/3TC/TDF Switch (Switch From EFV/FTC/TDF at Week 96) Ext 22/173 (1.2%)9/173 (5.2%)—
DOR/3TC/TDF Only (DOR/3TC/TDF From Day 1) Ext 30/121 (0%)2/121 (1.7%)—
DOR/3TC/TDF Switch (Switch From EFV/FTC/TDF at Week 96) Ext 30/111 (0%)7/111 (6.3%)—
Most frequent serious events
Showing 10 of 112
Most frequent serious events
EventDOR/3TC/TDF Only (From Day 1) at Base StudyDOR/3TC/TDF Switch at Week 96 Base StudyDOR/3TC/TDF Only (DOR/3TC/TDF From Day 1) Ext 1DOR/3TC/TDF Switch (Switch From EFV/FTC/TDF at Week 96) Ext 1DOR/3TC/TDF Only (DOR/3TC/TDF From Day 1) Ext 2DOR/3TC/TDF Switch (Switch From EFV/FTC/TDF at Week 96) Ext 2DOR/3TC/TDF Only (DOR/3TC/TDF From Day 1) Ext 3DOR/3TC/TDF Switch (Switch From EFV/FTC/TDF at Week 96) Ext 3
COVID-19Infections and infestations0/3640/3640/2910/2690/1920/1730/1212/111
AppendicitisInfections and infestations1/3641/3640/2911/2690/1920/1730/1211/111
SepsisInfections and infestations0/3641/3640/2910/2690/1920/1730/1211/111
MyopericarditisCardiac disorders0/3640/3640/2910/2690/1920/1730/1211/111
InflammationGeneral disorders0/3640/3640/2910/2690/1920/1730/1211/111
Clostridium difficile colitisInfections and infestations0/3640/3640/2910/2690/1920/1730/1211/111
Cytomegalovirus colitisInfections and infestations0/3640/3640/2910/2690/1920/1730/1211/111
Facial bones fractureInjury, poisoning and procedural complications0/3640/3640/2910/2690/1920/1730/1211/111
Limb injuryInjury, poisoning and procedural complications0/3640/3640/2910/2690/1920/1730/1211/111
Anaplastic large-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3640/3640/2910/2690/1920/1730/1211/111
Most frequent other events
Showing 10 of 16
Most frequent other events
EventDOR/3TC/TDF Only (From Day 1) at Base StudyDOR/3TC/TDF Switch at Week 96 Base StudyDOR/3TC/TDF Only (DOR/3TC/TDF From Day 1) Ext 1DOR/3TC/TDF Switch (Switch From EFV/FTC/TDF at Week 96) Ext 1DOR/3TC/TDF Only (DOR/3TC/TDF From Day 1) Ext 2DOR/3TC/TDF Switch (Switch From EFV/FTC/TDF at Week 96) Ext 2DOR/3TC/TDF Only (DOR/3TC/TDF From Day 1) Ext 3DOR/3TC/TDF Switch (Switch From EFV/FTC/TDF at Week 96) Ext 3
DizzinessNervous system disorders37/364139/3642/2914/269————
DiarrhoeaGastrointestinal disorders50/36458/36416/29117/269————
HeadacheNervous system disorders58/36456/36418/29116/269————
NasopharyngitisInfections and infestations50/36443/36440/29126/269————
RashSkin and subcutaneous tissue disorders20/36450/3648/2915/269————
Abnormal dreamsPsychiatric disorders18/36444/3640/2912/269————
NauseaGastrointestinal disorders31/36442/3645/2917/269————
Upper respiratory tract infectionInfections and infestations41/36430/36421/29119/269————
InsomniaPsychiatric disorders24/36438/3646/29110/269————
PharyngitisInfections and infestations30/36420/36413/29111/269————

Baseline characteristics

The Baseline Analysis Population consists of all randomized participants who received ≥1 dose of study drug.

Age, Continuous
Age, Continuous(Years)MK-1439A (DOR/3TC/TDF From Day 1)ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96)Total
Mean33.6 ± 10.532.7 ± 9.933.1 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)MK-1439A (DOR/3TC/TDF From Day 1)ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96)Total
Female5953112
Male305311616
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MK-1439A (DOR/3TC/TDF From Day 1)ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96)Total
American Indian or Alaska Native10616
Asian5965124
Native Hawaiian or Other Pacific Islander000
Black or African American6768135
White177170347
More than one race5155106
Unknown or Not Reported000
Baseline cluster of differentiation 4 (CD4) cell counts
Baseline cluster of differentiation 4 (CD4) cell counts(cells/mm^3)MK-1439A (DOR/3TC/TDF From Day 1)ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96)Total
Mean434.9 ± 217.9415.5 ± 210.6425.2 ± 214.3
Baseline fasting low-density lipoprotein cholesterol (LDL-C)
Baseline fasting low-density lipoprotein cholesterol (LDL-C)(mg/dL)MK-1439A (DOR/3TC/TDF From Day 1)ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96)Total
Mean92.08 ± 32.3290.47 ± 30.6491.27 ± 31.48
Baseline fasting non-high-density lipoprotein cholesterol (non-HDL-C)
Baseline fasting non-high-density lipoprotein cholesterol (non-HDL-C)(mg/dL)MK-1439A (DOR/3TC/TDF From Day 1)ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96)Total
Mean115.39 ± 34.67114.63 ± 33.55115.01 ± 34.09
Baseline fasting cholesterol
Baseline fasting cholesterol(mg/dL)MK-1439A (DOR/3TC/TDF From Day 1)ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96)Total
Mean157.29 ± 36.43156.07 ± 36.51156.68 ± 36.45
Baseline fasting triglycerides
Baseline fasting triglycerides(mg/dL)MK-1439A (DOR/3TC/TDF From Day 1)ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96)Total
Mean120.85 ± 83.06123.23 ± 82.73122.04 ± 82.84

1 further baseline measures are reported on the registry.

08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Orkin C, Squires KE, Molina JM, Sax PE, Sussmann O, Lin G, Kumar S, Hanna GJ, Hwang C, Martin E, Teppler H. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial. Clin Infect Dis. 2021 Jul 1;73(1):33-42. doi: 10.1093/cid/ciaa822. PubMed 33336698 ↗
  • Orkin C, Molina JM, Lombaard J, DeJesus E, Rodgers A, Kumar S, Martin E, Hanna G, Hwang C. Once-daily Doravirine in Human Immunodeficiency Virus Type 1-Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis. Clin Infect Dis. 2020 Mar 17;70(7):1344-1352. doi: 10.1093/cid/ciz424. Erratum In: Clin Infect Dis. 2020 Jan 2;70(2):360. doi: 10.1093/cid/ciz1094. PubMed 31121015 ↗
  • Thompson M, Orkin C, Molina JM, Sax P, Cahn P, Squires K, Xu X, Rodgers A, Kumar S, Teppler H, Martin E, Hanna G, Hwang C. Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus-1: An Integrated Safety Analysis. Clin Infect Dis. 2020 Mar 17;70(7):1336-1343. doi: 10.1093/cid/ciz423. PubMed 31121013 ↗
  • Orkin C, Squires KE, Molina JM, Sax PE, Wong WW, Sussmann O, Kaplan R, Lupinacci L, Rodgers A, Xu X, Lin G, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C, Martin EA; DRIVE-AHEAD Study Group. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial. Clin Infect Dis. 2019 Feb 1;68(4):535-544. doi: 10.1093/cid/ciy540. PubMed 30184165 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in Mar 2017, 21 months.

Results were first posted in Apr 2018, 1 year 1 month after primary completion.

Of 34 industry-sponsored phase 3 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 27. This study's 21 months is close to that.

Counting every sponsor, half of 65 studies reached it within 26 months; a quarter within 19 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2015
First posted
Mar 31, 2015
StartActual
Jun 5, 2015
Primary completionActual
Mar 20, 2017
CompletionActual
Sep 7, 2023
Results first posted
Apr 30, 2018
Last update
Nov 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02403674
Responsible party
Sponsor
First posted
Mar 31, 2015
Start date
Jun 5, 2015
Primary completion
Mar 20, 2017
Completion
Sep 7, 2023
Results posted
Apr 30, 2018
Last update
Nov 20, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Doravirine · Tenofovir · Lamivudine

Start the discussion